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Abstract
Objective: Intravenous adenosine induces temporary bradycardia. This is due to the activation of extracellular adenosine
receptors (ARs). While adenosine can signal through any of four ARs (A1AR, A2AAR, A2BAR, A3AR), previous ex vivo studies
implicated the A1AR in the heart-rate slowing effects. Here, we used comparative genetic in vivo studies to address the
contribution of individual ARs to the heart-rate slowing effects of intravascular adenosine.
Methods and Results: We studied gene-targeted mice for individual ARs to define their in vivo contribution to the heart-
rate slowing effects of adenosine. Anesthetized mice were treated with a bolus of intravascular adenosine, followed by
measurements of heart-rate and blood pressure via a carotid artery catheter. These studies demonstrated dose-dependent
slowing of the heart rate with adenosine treatment in wild-type, A2AAR
2/2, A2BAR
2/2,o rA3AR
2/2 mice. In contrast,
adenosine-dependent slowing of the heart-rate was completely abolished in A1AR
2/2 mice. Moreover, pre-treatment with a
specific A1AR antagonist (DPCPX) attenuated the heart-rate slowing effects of adenosine in wild-type, A2AAR
2/2,o r
A2BAR
2/2 mice, but did not alter hemodynamic responses of A1AR
2/2 mice.
Conclusions: The present studies combine pharmacological and genetic in vivo evidence for a selective role of the A1AR in
slowing the heart rate during adenosine bolus injection.
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Introduction
The first published observation that intravascular adenosine
causes a temporary heart block dates back to 1927, when Drury
and Szent-Gyorgyi from the University of Cambridge, United
Kingdom, injected extracts from cardiac tissues intravenously into
a whole animal. They noticed a transient decrease of the cardiac
rhythm and slowing of the heart rate [1]. Following several
purification steps, the authors were able to identify the biologically
active compound of the extract as an ‘‘adenine compound’’ [1]. It
took almost 50 years from these early discoveries of the heart-rate-
slowing effects of ‘‘adenine compounds’’ [1] to the clinical use of
adenosine in treating patients with supraventricular tachycardia
[2]. As of today, intravenous adenosine has remained a mainstay
therapy for diagnosing or treating supraventricular arrhythmias
[3].
Adenosine mediates its signaling effects through 4 adenosine
receptors (ARs): A1AR, A2AR, A2BAR and the A3AR [4].
Previous studies implicated the A1AR in the heart-rate slowing
effects of adenosine. This is based on direct and indirect effects
associated with the activation of cardiac A1ARs. Direct A1AR
signaling effects are thought to lead to a hyperpolarization of sinus
node cells as well as cells of the arterioventricular node (AV node)
primarily by inducing a potassium current through an inward
rectifier potassium channel (IKAdo) [5,6,7]. Indirect effects of
adenosine signaling on the heart rate may involve the ability of the
A1AR to induce an ‘‘anti-adrenergic’’ state by opposing the effect
of sympathetic nervous activation and b1-stimulation by lowering
intracellular cAMP levels [8]. Based on these finding it was
concluded that the A1AR causes the adenosine induced
bradycardia. However, these studies are limited to observations
based on pharmacologic or genetic in vitro studies in a
Langendorff apparatus [9]. At present, comparative genetic in
vivo studies have yet to confirm the selective role of the A1AR in
adenosine-mediated bradycardia.
To elucidate the contribution of individual ARs to adenosine-
induced bradycardia in vivo, we utilized mice with specific
deletions of each individual AR. In addition, we confirmed our
findings utilizing pharmacological approaches in wild-type or
gene-targeted mice for ARs. Consistent with previous ex vivo
studies, we found a selective role for the A1AR in adenosine-
mediated bradycardia in vivo.
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Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies. All experiments were in accordance with the
University of Colorado Denver guidelines for animal care and are
approved by the Institutional Animal Care and Use Committee at
the University of Colorado Denver.
Animals, Heart Rate and Arterial Pressure Measurements
Experiments were performed in 12- to 14-week-old, previously
described, A1AR
2/2[10], A2BA
2/2 [11]or A3AR
2/2 [12] on the
C57BL/6 strain and in A2AR
2/2[13] on the CD1 strain or littermate
controls matched in age, gender and weight. In addition, studies in
wild-type mice were carried out in C57BL/6. Mice were anesthetized,
intubated and mechanical ventilated as described previously [14]. A
polyethelene catheter was inserted in the right carotid artery as
described previously [15,16]. The catheter was connected to a
Deltran
H pressure transducer (Utah Medical Products Inc., Salt Lake
City, UT, USA) located at the same hydrostatic level as the mouse,
which was connected to the CyQ BMP02 system (CyberSense, Inc.,
Nicholasville, KY, USA) designed to measure invasively systolic,
diastolic, pulse pressure, mean arterial blood pressure (MAP) and
heart rate (HR). Due to a sampling rate of 1,000 Hz, the device
automatically calculates HR from the amplitude of the pressure signal.
To correct HR measurement by the BMP02 for movement artifact
etc. an electrocardiogram (ECG) monitor (Hewlett-Packard, Bo ¨blin-
gen, Germany) was connected throughout the experiments. Adeno-
sine was given via the arterial catheter in a volume of 100 mL. All mice
were euthanized following the experimental protocol utilizing a lethal
dose of pentobarbital followed by cervical dislocation.
Pharmacological Compounds
Adenosine was dissolved in 0.9% NaCl solution (1 mg/ml).
DPCPX was dissolved in Ethanol (stock solution10 mmol/l). All
solutions were prepared on the day of the experiment. DPCPX
was applied by i.p. injection in dose of 1 mg/kg 30 min prior to
adenosine treatment. This dose of DPCPX was described
previously to sufficiently block A1AR [17]. All substances were
purchased from Sigma-Aldrich.
Data Analysis and Calculation
The mean of HR and MAP at 30 s prior to the injection of drugs
were taken as baseline values. The lowest value after drug injection
was taken as the minimum (HR or MAP). The percentage of
maximal change of HR and MAP was calculated using the formula:
Percentchange=Minimum/Baseline*100.Data werecomparedby
2-factor ANOVA or by Student t test when appropriate. Data are
expressed as mean6SEM. Values of P,0.05 were considered
statistically significant. For statistical analyses, GraphPad Prism 5.0
software for Windows XP (GraphPad Software, San Diego, Calif)
was used, calculation of percentage of change were performed using
Excel 2007
H (Microsoft
H, Redmond, WA, USA).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Wild type mice show decrease heart rate and mean
arterial pressure in response to adenosine bolus injection
Results from previous studies suggest that adenosine induces
bradycardia by activation of A1AR. This is based on pharmaco-
logic or genetic ex vivo studies. However, comparative in vivo
studies on the heart-rate slowing effects of adenosine in gene-
targeted mice for individual ARs have not been performed. To
study the effects of vascular adenosine injection on the heart-rate,
we inserted a polyethylene catheter into the common carotid
artery (see Figure 1). Next, we injected 25, 50 mg or 100 mgo f
adenosine via the carotid artery catheter. Higher doses of
adenosine were also tested, however did not show additional
effects on the heart-rate (data no shown). Adenosine caused a dose
dependent decline in heart rate (Figure 2A) and blood pressure
(Figure 2B). With increasing doses, magnitude and duration of the
response increased. Injection of a corresponding volume of vehicle
solution (150 ml normal saline) also caused a decrease in HR
(Figure 2C) and blood pressure (Figure 2D), however to a much
smaller extent than adenosine. Taken together, these data show
that intravascular bolus injection of adenosine is associated with a
dose-dependent slowing of the heart rate in this murine model
system, consistent with the notion of adenosine-induced heart
block seen in patients following adenosine-treatment of supraven-
tricular tachycardia.
Figure 1. Invasive measurement of hemodynamic parameters
in mice. Mice were anesthetized with pentobarbital, mechanical
ventilation was instituted and mice were ventilated using pressure-
controlled settings (inspiratory pressure of 15 mbar, positive end-
exspiratory pressure 5 mbar, 60% inspired oxygen concentration). The
common carotid artery was cannulated utilizing a polyethylene tube.
The arterial catheter was connected to a pressure transducer which
automatically calculated the HR by analyzing the amplitude of the
pressure signal. For verification of heart measurements, an electrocar-
diogram (ECG) monitor was connected throughout the experiment.
Values were recorded to computer hard drive for further analysis.
doi:10.1371/journal.pone.0006784.g001
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induced slowing of the heart-rate
After having established a murine model for studying adeno-
sine-mediated slowing of the heart rate in vivo, we next assessed
the contribution of individual ARs. Based on studies indicating
A1AR signaling in the negative chronotropic effects of adenosine,
we first pursued studies in previously characterized mice gene-
targeted for the A1AR [10]. In contrast to our findings in wild-type
mice, the heart-rate slowing effect of vascular adenosine infection
was abolished in gene-targeted mice for the A1AR (Figure 3).
Taken together, these studies provide genetic in vivo evidence for
the A1AR in the heart-rate slowing effects of vascular adenosine.
Negative chronotropic effects of vascular adenosine are
maintained in mice gene targeted for A2AAR, A2BAR or
A3AR
Since all 4 ARs are expressed in murine cardiac tissues [11], we
next studied the contribution of other ARs to the heart-rate
slowing effects induced by adenosine bolus injection. For this
purpose, we treated A2AAR
2/2, A2BAR
2/2 or A3AR
2/2 with
incremental doses of intravascular adenosine. As shown in
Figure 4, the heart rate decreased in all tested genotypes to a
similar degree. In fact, we observed no difference between gene-
targeted mice or their corresponding littermate controls. These
studies provide genetic evidence that even though the A2AAR,
Figure 2.Changes of blood pressureandheart-rate followingvascular adenosine injection.Following insertionofa catheter intothe common
carotid artery, mean arterial blood pressure and heart rate were measured. Intravascular bolus injection of adenosine as indicated. (A, B) Wild type mice
receivedvehicle (normalsaline) or adenosineat indicateddoses (100 ml). (C,D)Relativechangein meanarterial bloodpressure or heart-rate.(A,B:* p,0.05;
n=8;mean6SEM).
doi:10.1371/journal.pone.0006784.g002
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not mediate the heart-rate slowing effects of adenosine.
A1AR inhibitor DPCPX abrogates adenosine-induced
bradycardia in wild-type mice
The data gathered so far suggest that the A1AR plays an
important role in hemodynamic responses to systemic adenosine.
In order to circumvent possible adaptive mechanisms that might
be present in gene targeted mice (biological compensation), we
next sought to further characterize the role of A1AR using a
pharmacological approach. Here we utilized the effect of the
selective A1AR inhibitor DPCPX (1 mg/kg i.p.) in wild type mice
[17,19,20]. Figure 5A and B show that bradycardia to systemic
adenosine is strongly attenuated following the administration of
DPCPX. Taken together, such studies suggest that pharmacolog-
ical inhibition – similar to genetic deletion – of the A1AR dampens
adenosine-dependent heart-rate responses in vivo.
DPCPX attenuates bradycardia in AR gene targeted mice,
except A1AR
2/2 mice
To further study the influence of A1AR on hemodynamic
responses to adenosine, we next investigated the effect of the
Figure 3. Adenosine bolus injections in gene-targeted mice for the A1AR. Following insertion of a catheter into the common carotid artery,
mean arterial blood pressure and heart rate were measured A1AR
2/2-mice received bolus injection of vehicle or indicated doses of adenosine (100 ml)
via the carotid artery catheter. (A, B) Heart-rate and blood pressure responses to 100 mg of adenosine compared to wild type mice. (C, D) Relative
changes in heart-rate and mean arterial blood pressure. Note: A1AR
2/2-mice experience no change in HR following bolus injection of adenosine. (n=7–8;
WT n=8, *p,0.05 A1AR
2/2 vs WT; #p,0.05 compared to adenosine-vehicle; mean6SEM;).
doi:10.1371/journal.pone.0006784.g003
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As shown in Figure 6, treatment with DPCPX prevented bra-
dycardia after systemic adenosine bolus injection in A2AAR
2/2
and A2BAR
2/2 mice. As expected, DPCPX had no effect in
A1AR
2/2 mice. Taken together these studies suggest selectivity of
DPCPX for the A1AR, and confirm our genetic studies that
adenosine-mediated slowing of the heart-rate is selectively
mediated by the A1AR.
Figure 4. Effect of systemic adenosine administration in AR gene targeted mice. Following insertion of a catheter into the common carotid
artery, mean arterial blood pressure and heart rate were measured. A2AAR
2/2, A2BAR
2/2 orA3AR
2/2 received bolus injections of vehicle solution or
indicated doses of adenosine in 100 ml of vehicle. Change in heart-rate and mean arterial pressure compared to littermate control mice. (A, B)
A2AAR
2/2 (C, D) A2BAR
2/2 (E, F) A3AR
2/2 (n=6–8, *p,0.05 compared to adenosine-vehicle; mean6SEM).
doi:10.1371/journal.pone.0006784.g004
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Extracellular adenosine represents an endogenous distress
signal, particularly generated under injurious conditions such as
hypoxia or ischemia [21,22]. Under such circumstances, extracel-
lular adenosine signaling plays a critical role in attenuating
hypoxia-induced tissue injury and inflammation [4,23]. It elicits its
signaling effects through any of four ARs, which are highly
conserved among vertebrates [4]. In addition to its role in
hypoxia-adaptation [18,24,25] and attenuation of inflammation
[26,27,28], adenosine is known to cause significant slowing of the
heart rate, when injected intravenously. In this study, we
investigated the contribution of different ARs to the heart-rate
slowing effects of vascular adenosine utilizing genetic and
pharmacological in vivo approaches. We found that adenosine
caused a dose dependent decrease in heart rate in wild type mice,
which was completely abolished in gene-targeted mice for the
A1AR or following pre-treatment with the A1AR antagonist
DPCPX. In contrast, studies in A2AAR
2/2, A2BAR
2/2 or
A3AR
2/2 mice demonstrated heart-rate slowing following vascular
adenosine injection, suggesting a high degree of selectivity for the
A1AR-mediated role in slowing of the heart-rate.
Figure 5. Effect of A1AR antagonist DPCPX on adenosine-induced slowing of the heart-rate. Following insertion of a catheter into the
common carotid artery, mean arterial blood pressure and heart rate were measured after injection of vehicle or adenosine at indicated doses (volume
of 100 ml). All animals received 1 mg/kg of the A1AR antagonist DPCPX (i.p., 30 min prior to the experimental procedure) or vehicle. (A, B) Heart-rate
or mean arterial blood pressure at indicated time points. (C, D) Relative changes of heart-rate or mean arterial blood pressure (n=4, * indicates p,0.05
compared to DPCPX treatment; #indicates p,0.05 compared to adenosine-vehicle injection; mean6SEM).
doi:10.1371/journal.pone.0006784.g005
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system (CNS) adenosine signaling in the regulation of blood
pressure, temperature and sleep-awake cycle. Of particular
interest has been the non-specific adenosine receptor antagonist
caffeine. As such, caffeine is a CNS stimulant, having the effect
of temporarily warding off drowsiness, restoring alertness and
elevating blood pressure and heart-rate. In fact, caffeine is the
world’s most widely consumed psychoactive substance. The
question through which adenosine receptors the stimulating
effects of caffeine are mediated has been the center of several
research studies. First evidence comes from studies in gene-
targeted mice for the A2AAR [13]. The authors found that
A2AAR
2/2 mice showed attenuated exploratory activity,
whereas caffeine, which normally stimulates exploratory behav-
Figure 6. Effect of A1 adenosine receptor (AR) antagonist DPCPX in AR gene targeted mice. Following insertion of a catheter into the
common carotid artery, mean arterial blood pressure and heart rate were measured after injection of vehicle or adenosine at indicated doses (volume
of 100 ml). All animals received 1 mg/kg of the A1AR antagonist DPCPX (i.p., 30 min prior to the experimental procedure) or vehicle. Relative changes
in HR and MAP are displayed. (A, B) A1AAR
2/2 (C, D) A2AAR
2/2 (E, F) A2BAR
2/2 (n=4;* p,0.05 compared to DPCPX treated mice; #p,0.05 compared to
adenosine-vehicle; mean6SEM).
doi:10.1371/journal.pone.0006784.g006
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these mice had higher blood pressure and increased heart-rate
[13]. A second study in genetic models confirmed that caffeine
mediated arousal involves the A2A and not the A1AR [29].
Only recently, a very elegant and complete study from the
research group of Bertil Fredholm extended these findings
towards the physiological contributions of A1 and A2A
receptors in the regulation of heart rate, body temperature,
and locomotion as revealed using knockout mice and caffeine
[30]. Here, the authors studied heart rate, body temperature,
locomotor activity, and oxygen consumption in awake mice
lacking one or both of the A1AR or A2AAR using telemetry and
respirometry, before and after caffeine administration. When
compared with wild-type littermates, HR was higher in male
A1AR
2/2 mice but lower in A2AAR
2/2 mice. A single dose of
an unselective beta-blocker abolished the HR differences
between these genotypes, thus indicating that the studied
differences involve central nervous system mediated alterations
of heart rate and blood pressure. Taken together, these studies
indicate that the A2AAR plays an important role in the
modulation of oxygen comsumption, locomoter activity by acute
and chronic caffeine administration. There is also evidence for
effects of higher doses of caffeine being independent of both the
A1AR and the A2AAR [30].
Consistent with our studies indicating a role of the A1AR in
mediating acute responses to adenosine bolus injections, other
studies from Bertil Fredholm’s group indicated that the A1AR is
involved in the regulation of heart rate, body temperature and
locomotor activity, but the magnitude of the involvement is
different in males and females [31]. Female mice had higher heart
rate, body temperature and locomotion, both during daytime and
during the night. Awake A1AR
2/2 mice had a slightly elevated
heart rate, and this was more clear-cut in males. Heart rate was
also higher in Langendorff-perfused denervated A1AR
2/2 hearts.
Futhermore the bradycardic response to the adenosine receptor
agonist 2-chloroadenosine is absent in isolated A1AR
2/2 hearts,
which was demonstrated in very elegant studies from the research
group of John Headrick [9]. At present it remains somewhat
unclear how the central and peripheral mechanisms of adenosine
receptor dependent regulation of blood pressure and heart rate act
in concert.
While there is some overlap between these studies of Bertil
Fredholm’s group [30,31] and our present data, the main
differences between both studies are the mechanisms of adenosine
receptor mediated alterations in blood pressure, heart rate and
locomotion. While the studies above mainly focus on the
consequences of caffeine – a CNS stimulant that works through
inhibition of CNS adenosine receptors [30] or at baseline heart
rate levels without adenosine stimulation [31] – the present studies
address the role of peripheral adenosine receptors located in the
heart in mediating adenosine-dependent slowing of the hear-rate
following intravascular adenosine injection. In fact, intravascular
injection of adenosine is performed on a routine basis in patients
during the treatment of supraventricular tachycardia [3]. As such,
the present studies were performed in an in vivo setting following a
time interval of 30 s after adenosine receptor activation, while the
studies of Bertil Fredholm’s group examined non-anesthetized
mice over several days [30,31], or ex vivo Langendorf prepara-
tions [31].
Previous studies had shown that the A1AR can influences the
ion current in cardiac pacemakers, causing slower atrioventricular
nodal conduction, causing bradycardia as seen in this study [6,7].
The A1AR promoter is highly active in the atrium [32], leading to
high A1AR mRNA levels [31]. In fact, expressional levels of the
A1AR are higher in the atrium as compared to the ventricle
[33,34]. Furthermore, activation of A1AR by adenosine causes an
inhibition of adenylate cyclase, which results in decreased
intracellular levels of cAMP [35]. Thus, A1AR activation
counteracts the effect of the b1-adrenoceptor, which activates the
adenylate cylcase and increases cAMP levels [8]. In fact, in
transgenic mice, overexpressing the A1AR, it was shown that the
b-adrenoceptor sensitivity/reactivity was impaired, despite the
fact, that there is an enhanced b-adrenoceptor density in these
mice [36,37]. Moreover, isolated perfused hearts from A1AR
overexpressing mice had a lower resting heart rate when
compared to control animals [38]. Similarly, previous studies
hypothesized that the activation of the A1AR may also be a
potential cause for bradycardia in patients following cardiac
transplantation. In fact, these studies showed that administration
of the unspecific adenosine receptor antagonist theophylline leads
normalization of the heart rate in cardiac transplant recepients
[39]. However, as of to date it seems unclear whether the A1AR
has an influence on the heart rate under physiological conditions in
vivo. There are reports that A1AR deficient mice have similar
heart-rate as wild type controls [20]. In contrast, when hearts from
A1AR
2/2 mice are isolated, the heart rate measurements reveal a
higher heart-rate than in wild-type mice [31]. In the current study
in anesthetized mice, we did not see a difference in baseline heart-
rate when comparing A1AR
2/2 mice to littermate controls.
However, since anesthesia sufficiently blocks the influence of
sympathetic nervous system on the heart, we cannot draw
conclusion on the HR in the alert state. Other reports stated that
male A1AR
2/2 mice have a higher heart rate than wild type
littermates, suggesting that gender might influence A1AR function
of regulating HR [30].
Other ARs have also been suggested to influence the heart
rate in mice. A2AAR
2/2 deficient mice have a higher blood
pressure and heart rate when compared to wild type mice [13].
In the present study the response to intravascular adenosine of
A2AAR
2/2 mice was not altered when compared to that of
littermate controls. These findings suggest that the A2AAR does
not influence the cardiac conductance system directly in response
to systemic adenosine. It seems plausible that A2AAR, rather,
influences HR via central nervous system mediated mechanisms
[40].
Systemic adenosine, as used in present studies could simulta-
neously influence two important variables of the blood pressure:
cardiac output and vascular resistance. In the present study the
intravascular administration of adenosine leads to a decrease in
the mean arterial pressure, simultaneously with the observed
slowing of the heart-rate. It is important to point out that from
the current data, it is difficult to conclude which AR might
mediate the decrease in MAP (adenosine-mediated vasodilata-
tion). Both variables (HR and MAP) were altered simultaneously
in the experimental protocol. Various studies have assessed the
influence of ARs on arterioles and different adenosine receptors
might be involved in arteriolar dilatations, however there is
evidence that the A2AAR might play the most important role
[41,42,43,44].
Taken together, the present studies reveal a critical role of the
A1AR to adenosine bolus injection induced bradycardia in vivo.
A2AAR, A2BAR and A3AR [7] do not influence the response to
intravascular adenosine.
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